Literature DB >> 21461854

Serum adenosine deaminase may predict disease activity in rheumatoid arthritis.

Batool Zamani1, Raika Jamali, Arsia Jamali.   

Abstract

To determine the relationship between serum adenosine deaminase (ADA) and disease activity, and to develop a new disease activity index based on serum ADA in rheumatoid arthritis (RA). Seventy RA patients were included. Disease activity based on Disease Activity Score 28-ESR (DAS28-ESR) and Disease Activity Score 28-CRP (DAS28-CRP) and serum ADA were measured. There were correlations when serum ADA compared with DAS28-ESR and DAS28-CRP. (R (2) = 0.014, 0.175, respectively, P values < 0.00). New disease activity index was developed by replacing ADA with ESR and CRP in DAS28-ESR and DAS28-CRP. There were strong correlations when new model compared with DAS28-ESR and DAS28-CRP. (R (2) = 0.94 and 0.95, respectively, P values < 0.00) The best new model values corresponding to DAS28-ESR values of 2.6, 3.2, and 5.1 were 2.79, 3.4, and 4.82, respectively; and new model values corresponding to DAS28-CRP values of 2.3, 2.7, and 4.1 were 2.1, 2.9, and 4, respectively. There were agreements when the new model compared with DAS28-ESR and DAS28-CRP for determination of patients in different disease activity categories. (Kappa = 0.81 and 0.71, respectively, P values < 0.00). The new disease activity index that applies serum ADA may help in predicting disease activity in RA.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21461854     DOI: 10.1007/s00296-011-1912-0

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  37 in total

1.  Synovial fluid adenosine deaminase and high-sensitivity C-reactive protein activity in differentiating monoarthritis.

Authors:  Batool Zamani; Raika Jamali; Hassan Ehteram
Journal:  Rheumatol Int       Date:  2010-08-19       Impact factor: 2.631

2.  Correlation of serum levels of adenosine deaminase activity and its isoenzymes with disease activity in rheumatoid arthritis.

Authors:  R A Sari; S Taysi; O Yilmaz; N Bakan
Journal:  Clin Exp Rheumatol       Date:  2003 Jan-Feb       Impact factor: 4.473

3.  Comparative analysis of cerebrospinal fluid adenosine deaminase in tuberculous and non-tuberculous meningitis.

Authors:  Ali Moghtaderi; Abbasali Niazi; Roya Alavi-Naini; Saideh Yaghoobi; Behzad Narouie
Journal:  Clin Neurol Neurosurg       Date:  2010-07       Impact factor: 1.876

4.  Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis.

Authors:  M L Prevoo; M A van 't Hof; H H Kuper; M A van Leeuwen; L B van de Putte; P L van Riel
Journal:  Arthritis Rheum       Date:  1995-01

5.  Validity of single variables and composite indices for measuring disease activity in rheumatoid arthritis.

Authors:  D M van der Heijde; M A van't Hof; P L van Riel; M A van Leeuwen; M H van Rijswijk; L B van de Putte
Journal:  Ann Rheum Dis       Date:  1992-02       Impact factor: 19.103

6.  Comparison of Disease Activity Score (DAS)28- erythrocyte sedimentation rate and DAS28- C-reactive protein threshold values.

Authors:  Eisuke Inoue; Hisashi Yamanaka; Masako Hara; Taisuke Tomatsu; Naoyuki Kamatani
Journal:  Ann Rheum Dis       Date:  2006-08-22       Impact factor: 19.103

7.  A simplified disease activity index for rheumatoid arthritis for use in clinical practice.

Authors:  J S Smolen; F C Breedveld; M H Schiff; J R Kalden; P Emery; G Eberl; P L van Riel; P Tugwell
Journal:  Rheumatology (Oxford)       Date:  2003-02       Impact factor: 7.580

8.  Disease Activity Score 28 (DAS28) using C-reactive protein underestimates disease activity and overestimates EULAR response criteria compared with DAS28 using erythrocyte sedimentation rate in a large observational cohort of rheumatoid arthritis patients in Japan.

Authors:  Toshihiro Matsui; Yoshiaki Kuga; Atsushi Kaneko; Jinju Nishino; Yoshito Eto; Noriyuki Chiba; Masayuki Yasuda; Koichiro Saisho; Kota Shimada; Shigeto Tohma
Journal:  Ann Rheum Dis       Date:  2007-03-16       Impact factor: 19.103

9.  Serum and synovial fluid adenosine deaminase activity in patients with rheumatoid arthritis, osteoarthritis, and reactive arthritis.

Authors:  H Yuksel; T F Akoğlu
Journal:  Ann Rheum Dis       Date:  1988-06       Impact factor: 19.103

10.  Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score.

Authors:  Daniel Aletaha; Valerie P K Nell; Tanja Stamm; Martin Uffmann; Stephan Pflugbeil; Klaus Machold; Josef S Smolen
Journal:  Arthritis Res Ther       Date:  2005-04-07       Impact factor: 5.156

View more
  15 in total

Review 1.  Purinergic signalling in the musculoskeletal system.

Authors:  Geoffrey Burnstock; Timothy R Arnett; Isabel R Orriss
Journal:  Purinergic Signal       Date:  2013-08-14       Impact factor: 3.765

2.  Co-Nanoencapsulation of Vitamin D3 and Curcumin Regulates Inflammation and Purine Metabolism in a Model of Arthritis.

Authors:  Jean Lucas G da Silva; Daniela F Passos; Viviane M Bernardes; Fernanda L Cabral; Paulo G Schimites; Alessandra G Manzoni; Edilene Gadelha de Oliveira; Cristiane de Bona da Silva; Ruy Carlos Ruver Beck; Matheus H Jantsch; Roberto M Maciel; Daniela B R Leal
Journal:  Inflammation       Date:  2019-10       Impact factor: 4.092

3.  Serum anti-cyclic citrullinated peptide antibodies may predict disease activity in rheumatoid arthritis.

Authors:  Kamal Esalatmanesh; Raika Jamali; Arsia Jamali; Bardia Jamali; Mohammadreza Nikbakht
Journal:  Rheumatol Int       Date:  2011-12-21       Impact factor: 2.631

4.  No association between serum adenosine deaminase activity and disease activity in Crohn's disease.

Authors:  Mahmoud Sajjadi; Ali Gholamrezaei; Nasser Ebrahimi Daryani
Journal:  Dig Dis Sci       Date:  2015-02-05       Impact factor: 3.199

Review 5.  Pharmacological Aspects of Natural Quercetin in Rheumatoid Arthritis.

Authors:  Mengshi Tang; Yan Zeng; Weijun Peng; Xi Xie; Yongyu Yang; Biting Ji; Fen Li
Journal:  Drug Des Devel Ther       Date:  2022-06-29       Impact factor: 4.319

6.  Serum levels of calreticulin in correlation with disease activity in patients with rheumatoid arthritis.

Authors:  Min Ni; Wei Wei; Yichao Wang; Na Zhang; Hongmei Ding; Chen Shen; Fang Zheng
Journal:  J Clin Immunol       Date:  2013-03-27       Impact factor: 8.317

7.  Serum adenosine deaminase activity is increased in systemic lupus erythematosus patients and correlated with disease activity.

Authors:  Zhao-Wei Gao; Guan-Hua Zhao; Zhe Zhang; Jing Huang; Zi-Yue Li; Hui-Zhong Zhang; Ke Dong
Journal:  Immunol Res       Date:  2018-04       Impact factor: 2.829

8.  Serum Adenosine Deaminase as Inflammatory Marker in Rheumatoid Arthritis.

Authors:  Kiranmayi S Vinapamula; Srinivasarao V L N Pemmaraju; Siddartha Kumar Bhattaram; Aparna R Bitla; Suchitra M Manohar
Journal:  J Clin Diagn Res       Date:  2015-09-01

Review 9.  Mechanism of action of methotrexate in rheumatoid arthritis, and the search for biomarkers.

Authors:  Philip M Brown; Arthur G Pratt; John D Isaacs
Journal:  Nat Rev Rheumatol       Date:  2016-10-27       Impact factor: 20.543

10.  A2A and A3 adenosine receptor expression in rheumatoid arthritis: upregulation, inverse correlation with disease activity score and suppression of inflammatory cytokine and metalloproteinase release.

Authors:  Katia Varani; Melissa Padovan; Fabrizio Vincenzi; Martina Targa; Francesco Trotta; Marcello Govoni; Pier Andrea Borea
Journal:  Arthritis Res Ther       Date:  2011-12-06       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.